This article is more than 5 years old. Information may no longer be current.

Aerie reports net loss for fourth quarter, full year

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Aerie Pharmaceuticals reported a GAAP net loss of $10.3 million, or $0.62 per share, for the fourth quarter ending Dec. 31, 2013, bringing the year-end GAAP net loss to $31.6 million, or $6.38 per share, according to a press release.

GAAP net loss was $3.8 million, or $4.01 per share, and $15.6 million, or $16.39 per share, for the respective time periods the prior year.

Aerie reported being on track with clinical programs for triple-action ophthalmic solution candidate AR-13324 and quadruple-action ophthalmic solution candidate PG324. Proposed trade names for the solutions are Rhopressa and Roclatan, respectively.

Phase 3 trials of Rhopressa are expected to begin early in the third quarter, with efficacy data projected to be available in the middle of 2015. A phase 2b study of Roclatan is under way, with efficacy data projected to be available later this year.